Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
抗生素和抗病毒
/
抗感染
功能 结构
/
植物组织培养抗生素
头孢烯类 Antibacterial
/ Cefotaxime sodium/头孢噻肟钠盐

Cefotaxime sodium/头孢噻肟钠盐 {[allProObj[0].p_purity_real_show]}

货号：A468233 同义名： 头孢噻肟钠 / Cefotaxim sodium; HR-756 sodium

Cefotaxime sodium是一种第三代头孢菌素类抗生素，通过结合青霉素结合蛋白（PBPs）抑制肽聚糖合成终末转肽反应，破坏细胞壁完整性。Cefotaxime sodium具有强β-内酰胺酶稳定性，常用于农杆菌介导转化实验及与万古霉素联用控制细菌污染，有效浓度（50-500 mg/L）。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cefotaxime sodium/头孢噻肟钠盐 化学结构 CAS号：64485-93-4
Cefotaxime sodium/头孢噻肟钠盐 化学结构
CAS号：64485-93-4
Cefotaxime sodium/头孢噻肟钠盐 3D分子结构
CAS号：64485-93-4
Cefotaxime sodium/头孢噻肟钠盐 化学结构 CAS号：64485-93-4
Cefotaxime sodium/头孢噻肟钠盐 3D分子结构 CAS号：64485-93-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cefotaxime sodium/头孢噻肟钠盐 纯度/质量文件 产品仅供科研

货号：A468233 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Cefotaxime sodium/头孢噻肟钠盐 生物活性

描述 The cefotaxime sodium spectrum of activity is very broad and includes many common species and a variety of less frequently isolated pathogens. Cefotaxime was consistently active against Actinobacillus actinomycetemcomitans, Capnocytophaga spp, Eikenella corrodens, Erysipelothrix rhusiopathiae, Pasteurella multocida, Plesiomonas shigelloides, and Fusobacterium nucleatum[3]. The stability of cefotaxime sodium was dependent on the surface area of the excipient in contact with the drug[4]. Ceftriaxone may be more versatile having the additional apparent benefits of reducing other postoperative infections, being less dependent on metronidazole as an adjunct and providing a more effective prophylactic cover against Staphylococcus aureus[5]. Moreover, Ceftriaxone and cefotaxime are both effective in the treatment of bacterial meningitis[6].

Cefotaxime sodium/头孢噻肟钠盐 细胞实验

Cell Line
Concentration Treated Time Description References
Vibrio vulnificus 0.05 mg/ml 8 h Evaluate the inhibitory activity of cefotaxime alone against V. vulnificus, initial inhibition for 8 h followed by regrowth Antimicrob Agents Chemother. 1997 Oct;41(10):2214-7
Vibrio vulnificus 0.03 mg/ml 2 h Evaluate the inhibitory activity of cefotaxime alone against V. vulnificus, initial inhibition for 2 h followed by regrowth Antimicrob Agents Chemother. 1997 Oct;41(10):2214-7
Salmonella Typhimurium 14028s 0.065 mg/l 3 h Evaluate the effect of sub-inhibitory concentration of cefotaxime on bacterial survival, results showed a 5-6 fold decrease in survival of bacteria exposed to cefotaxime Open Biol. 2015 Oct;5(10):150070
Aeromonas veronii C4 5 µg/ml 11 h To investigate the effect of tmRNA deletion on persister formation to cefotaxime, results showed that tmRNA deletion significantly increased persister cell production. Front Cell Infect Microbiol. 2020 Feb 28;10:44

Cefotaxime sodium/头孢噻肟钠盐 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
CBA female mice Urinary tract infection model Subcutaneous injection 100 mg/kg Every 2 or 4 hours for 24 hours Evaluate the efficacy of cefotaxime in a urinary tract infection model, showing that the combination of cefotaxime and amoxicillin-clavulanate was effective against CTX-M-15-type ESBL-producing E. coli strains Antimicrob Agents Chemother. 2015 Nov 2;60(1):424-30
Sprague-Dawley rats Neonatal rat experimental Escherichia coli sepsis model Subcutaneous injection 50 mg/kg Administered at 7.5 h and 24 h postinoculation To compare the neuroprotective effects of cefotaxime combined with moxifloxacin versus cefotaxime combined with gentamicin in preventing white matter damage in a neonatal rat model of experimental Escherichia coli sepsis. Results showed that the cefotaxime-moxifloxacin combination significantly reduced microglial activation and immature oligodendrocyte cell death and delayed myelination. Antimicrob Agents Chemother. 2011 Jul;55(7):3567-9
BALB/c mice Systemic infection model Intraperitoneal injection 0.065 mg/L Single injection, evaluated after 48 hours of infection Evaluate the effect of sub-inhibitory concentration of cefotaxime on systemic colonization, results showed enhanced colonization in liver and spleen for bacteria exposed to cefotaxime Open Biol. 2015 Oct;5(10):150070
BALB/c mice Peritonitis mouse model Intraperitoneal injection 150 mg/kg Twice daily for 36 hours Evaluation of the efficacy of mecillinam and cefotaxime combination therapy against CTX-M-15 WT and N135D mutant, showing significant reduction in bacterial load in liver and spleen Nat Commun. 2019 Feb 6;10(1):618

Cefotaxime sodium/头孢噻肟钠盐 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03067805 Sexual Infidelity ... 展开 >> Emotional Infidelity Jealousy 收起 << Not Applicable Recruiting November 2019 China, Sichuan ... 展开 >> School of Life Science and Technology, University of Electronic Science and Technology Recruiting Chengdu, Sichuan, China, 611731 Contact: Qin Li, Master       helenlee@uestc.edu.cn 收起 <<
NCT03053401 Post-operative Pain ... 展开 >> Quadriceps Muscle Strength 收起 << Not Applicable Recruiting June 30, 2019 United States, Ohio ... 展开 >> Akron Children's Hospital Recruiting Akron, Ohio, United States, 44308 Contact: Rami E Karroum, MD    330-543-8823    rkarroum@chmca.org    Contact: Ibrahim Farid, MD    330-543-8823    ifarid@chmca.org    Sub-Investigator: Ibrahim Farid, MD          Sub-Investigator: Paul Fleissner, MD          Sub-Investigator: Elizabeth Kendrick, MSN,RN          Sub-Investigator: Jonathan Klein, DO          Sub-Investigator: George Youssef, MD 收起 <<
NCT00726622 Colorectal Cancer Phase 3 Active, not recruiting - -

Cefotaxime sodium/头孢噻肟钠盐 参考文献

[1]Woodfield JC, Van Rij AM, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9.

[2]Scholz H, Hofmann T, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7.

[3]Cormican MG, Jones RN. Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Diagn Microbiol Infect Dis. 1995;22(1-2):43–48

[4]Al-Nimry SS, Alkhamis KA, Alzarieni KZ. The Effect of Specific Surface Area of Chitin-Metal Silicate Coprocessed Excipient on the Chemical Decomposition of Cefotaxime Sodium. J Pharm Sci. 2017;106(2):570–578

[5]Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003;185(1):45–49

[6]Scholz H, Hofmann T, Noack R, Edwards DJ, Stoeckel K. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998;44(2):142–147

Cefotaxime sodium/头孢噻肟钠盐 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.94mL

4.19mL

2.09mL

Cefotaxime sodium/头孢噻肟钠盐 技术信息

CAS号64485-93-4
分子式C16H16N5NaO7S2
分子量 477.45
SMILES Code O=C([O-])C(N1[C@@]([H])([C@@H](C1=O)NC(/C(C2=CSC(N)=N2)=N/OC)=O)SC3)=C3COC(C)=O.[Na+]
MDL No. MFCD00079073
别名 头孢噻肟钠 ;Cefotaxim sodium; HR-756 sodium; CTX; Cefotaxime(sodium salt); HR-756; Cefotaxime(sodium)
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C
溶解方案

DMSO: 45 mg/mL(94.25 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(104.72 mM)，配合低频超声助溶

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一

Tags: Cefotaxime sodium | Cefotaxim sodium;HR-756 sodium;CTX;Cefotaxime (sodium salt);HR-756 | 头孢噻肟钠 | Cephalosporin | Antibacterial | AmBeed-信号通路专用抑制剂 | Cefotaxime sodium/头孢噻肟钠盐 纯度/质量文件 | Cefotaxime sodium/头孢噻肟钠盐 生物活性 | Cefotaxime sodium/头孢噻肟钠盐 临床数据 | Cefotaxime sodium/头孢噻肟钠盐 参考文献 | Cefotaxime sodium/头孢噻肟钠盐 实验方案 | Cefotaxime sodium/头孢噻肟钠盐 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z